L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination ...

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ...

GCCs can serve as structured environments to pilot AI initiatives and identify scalable approaches beyond isolated ...

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective ...

Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDTCompany ParticipantsXi-Yong Fu ...

From practical skills in tech and marketing to effective communication, educational institutions must modernise curricula and ...

Title: Cancer Research UK first-in-human (FIH) phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 (HTL) as monotherapy and in combination with immunotherapy in ...

0.41 % Cu, 0.72 g/t Au, and 2.00 g/t Ag for 1.07% CuEq over 22.0 metre with an estimated true width of 17.6 metres, which represents a 50 metre down-dip extension of this zone and remains open for ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...

EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated ...